Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Atopic Dermatitis Clinical Trials Market

Atopic Dermatitis Clinical Trials Market Share

Report ID: GMI8508
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Atopic Dermatitis Clinical Trials Market Share

The atopic dermatitis clinical trials industry is dynamic and multifaceted, characterized by the presence of various stakeholders including pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic institutions. Trials often focus on efficacy, safety, and long-term effects, seeking to enhance patient outcomes and quality of life. Collaboration between researchers, healthcare institutions, and pharmaceutical entities drives progress in this dynamic field.

Atopic Dermatitis Clinical Trials Market Companies

Prominent players operating in the atopic dermatitis clinical trials industry include:

BIOCYTOGEN
Charles River Laboratories
Hooke Laboratories, LLC
Imavita
Novotech
Oncodesign services
QIMA LTD
Redoxis
REPROCELL Inc.
Syneos Health

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global atopic dermatitis clinical trials industry was valued at USD 2.4 billion in 2023 and will exhibit growth at 11.4% to reach USD 6.4 billion by 2032, driven by the rising prevalence of atopic dermatitis.

The outsourced segment accounted for majority of revenue share in 2023 and is expected to reach USD 3.9 billion by 2032, backed by the increased demand for novel treatment, the wider adoption of CROs, and access to specialized expertise.

North America atopic dermatitis clinical trials market accounted for USD 945.8 million in 2023 and is anticipated to record a CAGR of 10.8% through 2032, as the region possesses a robust research infrastructure with leading academic institutions, medical centers, and pharmaceutical companies.

BIOCYTOGEN, Charles River Laboratories, Hooke Laboratories, LLC, Imavita, Novotech, Oncodesign services, QIMA LTD., Redoxis, REPROCELL Inc., and Syneos Health.